1. Labcorp reported revenue growth of 9.8% in Q4 2024. 2. Guidance for 2025 predicts revenue increase between 6.7% and 8.0%. 3. Adjusted EPS is expected to rise to $15.60-$16.40 for 2025. 4. Organic growth in diagnostics and biopharma underscores Labcorp's strength. 5. A quarterly cash dividend of $0.72 per share was declared.
Positive revenue growth and strong EPS guidance can attract investor interest, similar to previous earnings beats influencing stock performance.
The earnings results, guidance, and dividend news are pivotal for investor outlook on LH.
The guidance and results are likely to influence investor sentiments quickly, similar to past quarterly earnings results impacting stock prices immediately.
BURLINGTON, N.C., Feb. 6, 2025 /PRNewswire/ -- Labcorp Holdings Inc. (NYSE: LH), a global leader of innovative and comprehensive laboratory services, today announced results for the fourth quarter ended December 31, 2024, and provided 2025 guidance.
"In 2024, Labcorp delivered exceptional results driven by both organic and inorganic growth," said Adam Schechter, chairman and CEO of Labcorp. "We announced 10 transactions to further establish our position as a trusted partner to hospitals, health systems and regional/local laboratories. Additionally, we strengthened our presence in key high growth areas including oncology, women's health, neurology and autoimmune disease. In 2025, we are positioned to deliver strong growth and margin expansion across both Diagnostics Laboratories and Biopharma Laboratory Services, while we improve health and improve lives of patients around the world."
In the fourth quarter, Labcorp advanced its position as a partner of choice for hospitals, health systems and regional/local laboratories:
The company also continued to make strides in science, technology and innovation:
On January 8, 2025, Labcorp announced a quarterly cash dividend of $0.72 per share of common stock, payable on March 12, 2025, to stockholders of record at the close of business on February 27, 2025.
| Three Months Ended Dec 31 | Year Ended Dec 31 | Delta |
|---|---|---|
| 2024 | 2024 | Revenue Summary (Dollars in billions) |
| Total Revenue $3.33 $3.03 9.8% |
$13.01 $12.16 7.0% |
7.0 % |
The following guidance assumes foreign exchange rates effective as of December 31, 2024, for the full year:
Labcorp (NYSE: LH) is a global leader of innovative and comprehensive laboratory services that helps doctors, hospitals, pharmaceutical companies, researchers and patients make clear and confident decisions. We provide insights and advance science to improve health and improve lives through our unparalleled diagnostics and drug development laboratory capabilities. The company's nearly 70,000 employees serve clients in approximately 100 countries.
For more information, visit www.Labcorp.com.
Cautionary Statement Regarding Forward-Looking Statements
This press release contains forward-looking statements, including, but not limited to, statements regarding the company's business and operating results. Please refer to the company's filings with the SEC for more details.